Skip to content
ContentLora

    Tip: press / anywhere to search.

    product

    Cytisinicline

    Cytisinicline is an investigational tablet that binds to nicotinic receptors, developed by Achieve Life Sciences (now trading as AchieveRx) to help adults quit smoking and vaping.[1][2] On 20 June 2026 the FDA issued a Complete Response Letter, which the company says concerned manufacturing inspection findings and unfinished labelling rather than efficacy or safety.[3] The company planned to resubmit in the fourth quarter of 2026 and anticipates a possible approval by mid-2027.[4]

    Editor reviewedStrict sourcingUpdated Wiki11 claims · 100% primaryDrugs, alcohol and addiction, Health and medicine
    Key facts

    Cytisinicline is an investigational stop-smoking medicine. It binds to nicotinic receptors and is being developed as an oral tablet to help adults quit smoking and vaping.[1] Its developer, Achieve Life Sciences, began doing business as AchieveRx in November 2026.[2] For the health effects of tobacco, see smoking and tobacco explained.

    This page is not medical advice. Anyone trying to quit should talk to a doctor or pharmacist about approved options.

    How it works

    Cytisinicline is a partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors.[5] In the ORCA-3 trial it reduced nicotine craving more than placebo, which the authors described as a mechanism of its effect.[5]

    Trial results

    ORCA-3 was a randomised, placebo-controlled phase 3 trial in 792 US adults who smoked at least 10 cigarettes a day. Participants took cytisinicline for 6 or 12 weeks or placebo, and all received behavioural support.[6] With the 12-week course, 30.3% were abstinent in weeks 9 to 12 versus 9.4% on placebo, and 20.5% versus 4.2% stayed abstinent from week 9 to week 24.[6] With the 6-week course, 14.8% were abstinent in weeks 3 to 6 versus 6.0%, falling to 6.8% versus 1.1% through week 24.[7] The trial reported no treatment-related serious adverse events. Several of its authors work for the developer.[8]

    The application also rests on an earlier phase 3 trial, ORCA-2, and a long-term open-label safety study, ORCA-OL.[9] In ORCA-OL, 479 adults still smoking or vaping after an earlier trial took cytisinicline for up to a year. The company reported four-week quit rates rising from 25.5% to 31.2% over the year and no new safety signals. The study had no placebo group.[10]

    The FDA decision

    On 20 June 2026 the FDA issued a Complete Response Letter. Achieve said the letter related to unresolved manufacturing inspection findings at its former third-party manufacturer and to labelling not finished by the action date. It said the FDA identified no deficiencies in clinical efficacy or safety.[3]

    The company moved finished-product manufacturing to Adare Pharma Solutions in the US. As of 10 November 2026 it planned to resubmit in the fourth quarter of 2026 and anticipated a possible approval by the end of the second quarter of 2027.[4]

    Vaping

    The FDA granted the vaping-cessation programme Breakthrough Therapy designation and a Commissioner’s National Priority Voucher. Achieve has completed a phase 2 vaping trial, ORCA-V1.[11] For background on e-cigarettes, see vaping explained.

    Drugs, alcohol and addiction: a crash course

    A sourced crash course on overdose, fentanyl, naloxone, addiction treatment, alcohol, tobacco, vaping, cannabis, kratom, gambling and where to get help.

    Questions readers ask

    What is cytisinicline?

    An investigational tablet that binds to nicotinic receptors in the brain, developed to help adults stop smoking and stop using e-cigarettes. It acts as a partial agonist and reduced nicotine craving in trials.[1][5]

    Is cytisinicline approved by the FDA?

    No. The FDA issued a Complete Response Letter on 20 June 2026. The company said it related to manufacturing inspection findings at a former contractor and to unfinished labelling, and that the FDA found no efficacy or safety deficiencies.[3]

    When could it be approved?

    The company planned to resubmit in the fourth quarter of 2026 and said in November 2026 that it anticipated a possible approval by the end of the second quarter of 2027.[4]

    How well did it work in trials?

    In the phase 3 ORCA-3 trial, 30.3% of people on a 12-week course were abstinent in weeks 9 to 12 versus 9.4% on placebo, and 20.5% versus 4.2% stayed abstinent through week 24.[6]

    Is it being studied for vaping?

    Yes. The FDA gave the vaping-cessation programme Breakthrough Therapy designation and a National Priority Voucher, and a phase 2 vaping trial has been completed.[11]

    Sources

    · 11 claims from 3 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Cytisinicline is an investigational compound that binds to nicotinic receptors, developed by Achieve Life Sciences as an oral tablet to help adults stop smoking and stop using e-cigarettes. confirmedas of 2026-11-10

    2. [2]

      On 9 November 2026 Achieve Life Sciences began doing business as AchieveRx and trading on Nasdaq under the ticker QUIT. confirmedas of 2026-11-10

    3. [3]

      On 20 June 2026 the FDA issued a Complete Response Letter on the cytisinicline application. Achieve said it related to unresolved manufacturing (cGMP) inspection findings at its former third-party manufacturer and to labelling not completed by the action date, and that the FDA identified no deficiencies in clinical efficacy or safety. confirmedas of 2026-08-11

    4. [4]

      Achieve moved finished-product manufacturing to Adare Pharma Solutions in the US and, as of 10 November 2026, planned to resubmit the application in the fourth quarter of 2026, anticipating a possible FDA approval by the end of the second quarter of 2027. confirmedas of 2026-11-10

    5. [5]

      Cytisinicline is a partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors, and in the ORCA-3 trial it reduced nicotine craving more than placebo. confirmedas of 2025-06-01

    6. [6]

      In the phase 3 ORCA-3 trial, 792 US adults who smoked at least 10 cigarettes a day were randomised to cytisinicline for 6 or 12 weeks or placebo, all with behavioural support. In weeks 9 to 12, 30.3% on 12 weeks of cytisinicline were abstinent versus 9.4% on placebo; from week 9 to week 24 the figures were 20.5% and 4.2%. confirmedas of 2025-06-01

    7. [7]

      In ORCA-3, 14.8% on 6 weeks of cytisinicline were abstinent in weeks 3 to 6 versus 6.0% on placebo, and 6.8% versus 1.1% stayed abstinent through week 24. confirmedas of 2025-06-01

    8. [8]

      ORCA-3 reported cytisinicline as well tolerated, with no treatment-related serious adverse events. The trial was funded by the developer, and several authors work for it. confirmedas of 2025-06-01

    9. [9]

      Achieve's New Drug Application for cytisinicline for smoking cessation in adults is supported by two completed phase 3 trials, ORCA-2 and ORCA-3, and the open-label long-term safety study ORCA-OL. confirmedas of 2026-11-10

    10. [10]

      In the open-label ORCA-OL study of 479 adults still smoking or vaping after an earlier ORCA trial, Achieve reported four-week quit rates rising from 25.5% in weeks 9 to 12 to 31.2% in weeks 49 to 52, with no new safety signals; the study had no placebo group. confirmedas of 2026-11-10

    11. [11]

      The FDA has granted cytisinicline's vaping-cessation programme Breakthrough Therapy designation and a Commissioner's National Priority Voucher; Achieve has completed a phase 2 vaping trial, ORCA-V1. confirmedas of 2026-11-10

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: May 14, 2027.

    Cite this page

    "Cytisinicline." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/cytisinicline

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.